REM  ||| S:0 E:4 ||| NNP
behaviour  ||| S:4 E:14 ||| JJ
disorder  ||| S:14 E:23 ||| NN
and  ||| S:23 E:27 ||| CC
neurodegenerative  ||| S:27 E:45 ||| JJ
diseases  ||| S:45 E:54 ||| NNS
Rapid-eye  ||| S:54 E:64 ||| JJ
movement  ||| S:64 E:73 ||| NN
( ||| S:73 E:74 ||| -LRB-
REM ||| S:74 E:77 ||| NNP
)  ||| S:77 E:79 ||| -RRB-
sleep  ||| S:79 E:85 ||| FW
behaviour  ||| S:85 E:95 ||| FW
disorder  ||| S:95 E:104 ||| FW
( ||| S:104 E:105 ||| -LRB-
RBD ||| S:105 E:108 ||| NNP
)  ||| S:108 E:110 ||| -RRB-
is  ||| S:110 E:113 ||| VBZ
an  ||| S:113 E:116 ||| DT
REM  ||| S:116 E:120 ||| NNP
sleep  ||| S:120 E:126 ||| NN
parasomnia  ||| S:126 E:137 ||| VBZ
characterized  ||| S:137 E:151 ||| VBN
by  ||| S:151 E:154 ||| IN
enactment  ||| S:154 E:164 ||| NN
of  ||| S:164 E:167 ||| IN
dream  ||| S:167 E:173 ||| NN
content  ||| S:173 E:181 ||| NN
during  ||| S:181 E:188 ||| IN
REM  ||| S:188 E:192 ||| NNP
sleep  ||| S:192 E:198 ||| VBP
associated  ||| S:198 E:209 ||| VBN
with  ||| S:209 E:214 ||| IN
loss  ||| S:214 E:219 ||| NN
of  ||| S:219 E:222 ||| IN
muscle  ||| S:222 E:229 ||| NN
atonia ||| S:229 E:235 ||| NN
.  ||| S:235 E:237 ||| .
RBD  ||| S:237 E:241 ||| NNP
can  ||| S:241 E:245 ||| MD
be  ||| S:245 E:248 ||| VB
either  ||| S:248 E:255 ||| DT
idiopathic  ||| S:255 E:266 ||| NN
or  ||| S:266 E:269 ||| CC
secondary  ||| S:269 E:279 ||| JJ
to  ||| S:279 E:282 ||| TO
drugs  ||| S:282 E:288 ||| NNS
or  ||| S:288 E:291 ||| CC
other  ||| S:291 E:297 ||| JJ
diseases ||| S:297 E:305 ||| NNS
.  ||| S:305 E:307 ||| .
The  ||| S:307 E:311 ||| DT
best  ||| S:311 E:316 ||| RBS
recognized  ||| S:316 E:327 ||| JJ
association  ||| S:327 E:339 ||| NN
is  ||| S:339 E:342 ||| VBZ
with  ||| S:342 E:347 ||| IN
neurodegenerative  ||| S:347 E:365 ||| JJ
diseases ||| S:365 E:373 ||| NNS
,  ||| S:373 E:375 ||| ,
namely  ||| S:375 E:382 ||| RB
alpha-synucleinopathies ||| S:382 E:405 ||| JJ
.  ||| S:405 E:407 ||| .
RBD  ||| S:407 E:411 ||| NNP
may  ||| S:411 E:415 ||| MD
represent  ||| S:415 E:425 ||| VB
the  ||| S:425 E:429 ||| DT
first  ||| S:429 E:435 ||| JJ
feature  ||| S:435 E:443 ||| NN
of  ||| S:443 E:446 ||| IN
neurodegeneration  ||| S:446 E:464 ||| NN
and  ||| S:464 E:468 ||| CC
can  ||| S:468 E:472 ||| MD
be  ||| S:472 E:475 ||| VB
considered  ||| S:475 E:486 ||| VBN
an  ||| S:486 E:489 ||| DT
early  ||| S:489 E:495 ||| JJ
marker  ||| S:495 E:502 ||| NN
of  ||| S:502 E:505 ||| IN
these  ||| S:505 E:511 ||| DT
disorders ||| S:511 E:520 ||| NNS
.  ||| S:520 E:522 ||| .
This  ||| S:522 E:527 ||| DT
review  ||| S:527 E:534 ||| NN
describes  ||| S:534 E:544 ||| VBZ
the  ||| S:544 E:548 ||| DT
main  ||| S:548 E:553 ||| JJ
clinical ||| S:553 E:561 ||| JJ
,  ||| S:561 E:563 ||| ,
pathogenetic ||| S:563 E:575 ||| NN
,  ||| S:575 E:577 ||| ,
and  ||| S:577 E:581 ||| CC
therapeutic  ||| S:581 E:593 ||| JJ
features  ||| S:593 E:602 ||| NNS
of  ||| S:602 E:605 ||| IN
RBD ||| S:605 E:608 ||| NNP
,  ||| S:608 E:610 ||| ,
pointing  ||| S:610 E:619 ||| VBG
to  ||| S:619 E:622 ||| TO
its  ||| S:622 E:626 ||| PRP$
association  ||| S:626 E:638 ||| NN
with  ||| S:638 E:643 ||| IN
neurodegenerative  ||| S:643 E:661 ||| JJ
diseases  ||| S:661 E:670 ||| NNS
and  ||| S:670 E:674 ||| CC
emphasizing  ||| S:674 E:686 ||| VBG
the  ||| S:686 E:690 ||| DT
clinical  ||| S:690 E:699 ||| JJ
and  ||| S:699 E:703 ||| CC
prognostic  ||| S:703 E:714 ||| JJ
implications ||| S:714 E:726 ||| NNS
.  ||| S:726 E:728 ||| .
